Condition: Promyelocytic Leukemia, Adult Acute · Sponsor: Grupo Argentino de Tratamiento de la Leucemia Aguda
This is a multicenter, observational real world clinical trial with prospective follow up that will evaluate the treatment outcome of acute promyelocytic leukemia (APL) patients in the first line with arsenic trioxide and all trans retinoic acid (ATO/ATRA) based regimens in Argentina.
This description comes directly from the study's public registry record.
Federico Sackmann, Dr. · +5491149720765 · fsackmann@fundaleu.org.ar
Paula Freigeiro · +5491140470052 · gatla.ar@gmail.com
Always discuss trial participation with your own doctor first.
| Hospital Italiano de La Plata | La Plata, Buenos Aires, Argentina | Recruiting |
| Instituto Privado de Hematologia y Hemoterapia | Paraná, Entre Ríos Province, Argentina | Recruiting |
| Hospital Escuela de Agudos Dr. Ramón Madariaga | Posadas, Misiones Province, Argentina | Recruiting |
| Hospital Descentralizado Dr. Guillermo Rawson | Rawson, San Juan Province, Argentina | Recruiting |
| CEMIC | CABA, Argentina | Recruiting |
| FUNDALEU | CABA, Argentina | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04897490